7.09
1.72%
+0.12
After Hours:
7.09
Titan Pharmaceuticals, Inc. (de) stock is currently priced at $7.09, with a 24-hour trading volume of 10,648.
It has seen a +1.72% increased in the last 24 hours and a -1.97% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.96 pivot point. If it approaches the $7.16 resistance level, significant changes may occur.
Previous Close:
$6.97
Open:
$7.31
24h Volume:
10,648
Market Cap:
$6.48M
Revenue:
$61,000
Net Income/Loss:
$-6.17M
P/E Ratio:
-12.44
EPS:
-0.57
Net Cash Flow:
$-6.43M
1W Performance:
-3.14%
1M Performance:
-1.97%
6M Performance:
+1,527%
1Y Performance:
+792.96%
Titan Pharmaceuticals, Inc. (de) Stock (TTNP) Company Profile
Name
Titan Pharmaceuticals, Inc. (de)
Sector
Industry
Phone
650 244 4990
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco
Titan Pharmaceuticals, Inc. (de) Stock (TTNP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-26-19 | Initiated | Maxim Group | Buy |
Nov-10-17 | Downgrade | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals, Inc. (de) Stock (TTNP) Latest News
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
GlobeNewswire Inc.
Gold Moves Lower; Microbot Medical Shares Slide
Benzinga
Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Nasdaq Down Over 100 Points; Fortress Biotech Shares Plummet
Benzinga
Why Titan Pharmaceuticals Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Benzinga
Titan Pharmaceuticals, Inc. (de) Stock (TTNP) Financials Data
Titan Pharmaceuticals, Inc. (de) (TTNP) Revenue 2024
TTNP reported a revenue (TTM) of $61.00 thousand for the quarter ending December 31, 2022, a -94.79% decline year-over-year.
Titan Pharmaceuticals, Inc. (de) (TTNP) Net Income 2024
TTNP net income (TTM) was -$6.17 million for the quarter ending September 30, 2023, a +39.44% increase year-over-year.
Titan Pharmaceuticals, Inc. (de) (TTNP) Cash Flow 2024
TTNP recorded a free cash flow (TTM) of -$6.42 million for the quarter ending September 30, 2023, a +16.40% increase year-over-year.
Titan Pharmaceuticals, Inc. (de) (TTNP) Earnings per Share 2024
TTNP earnings per share (TTM) was -$8.20 for the quarter ending September 30, 2023, a +52.33% growth year-over-year.
About Titan Pharmaceuticals, Inc. (de)
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Cap:
|
Volume (24h):